Related Experiment Videos
MCL-1 expression in B-cell non-Hodgkin's lymphomas
Jeong Hee Cho-Vega1, George Z Rassidakis, Joan H Admirand
1Department of Pathology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Human Pathology
|September 3, 2004
Summary
Myeloid cell leukemia-1 (MCL-1) protein is frequently expressed in high-grade B-cell lymphomas and plasma cell myeloma. This expression, predominantly the anti-apoptotic full-length isoform, correlates with lymphoma grade and may drive transformation.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- B-cell lymphomas express BCL-2 family proteins, including myeloid cell leukemia-1 (MCL-1).
- MCL-1 regulates B-cell viability and immortalization.
- MCL-1 exists as anti-apoptotic (full-length) and pro-apoptotic (short) isoforms.
Purpose of the Study:
- To assess MCL-1 expression in various B-cell lymphomas.
- To analyze the expression of MCL-1 isoforms in B-cell lymphoma cell lines.
Main Methods:
- Immunohistochemistry on 151 B-cell lymphomas.
- Western blot analysis on B-cell lymphoma cell lines.
Main Results:
- MCL-1 expression was more frequent and intense in high-grade (88%) versus low-grade (37%) lymphomas.
- MCL-1 expression positively correlated with increasing grade in follicular lymphomas.
- All plasma cell myeloma cases were MCL-1 positive.
- High-grade B-cell lymphoma cell lines predominantly expressed full-length MCL-1.
Conclusions:
- MCL-1 is frequently expressed in high-grade B-cell lymphomas and plasma cell myeloma, primarily as the anti-apoptotic full-length isoform.
- MCL-1 expression correlates with lymphoma grade and may contribute to follicular lymphoma transformation.